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Background: Adenosine monophosphate-activated protein kinases (AMPKs), as a
sensor of cellular energy status, have been known to play an important role in the
pathophysiology of diabetes and its complications. Because AMPKs are known to be
expressed in podocytes, it is possible that podocyte AMPKs could be an important
contributing factor in the development of diabetic proteinuria. We investigated the
roles of AMPKs in the pathological changes in podocytes induced by high-glucose
(HG) and advanced glycosylation end products (AGEs) in diabetic proteinuria.
Methods: We prepared streptozotocin-induced diabetic renal tissues and cultured
rat and mouse podocytes under diabetic conditions with AMPK-modulating agents.
The changes in AMPKα were analyzed with confocal imaging and Western blotting
under the following conditions: (1) normal glucose (5mM, ¼control); (2) HG
(30mM); (3) AGE-added; or (4) HG plus AGE-added.
Results: The density of glomerularphospho-AMPKa in experimental diabetic nephro-
pathy decreased as a function of the diabetic duration. Diabetic conditions including
HG and AGE changed the localization of phospho-AMPKa from peripheral cytoplasm to
internal cytoplasm and peri- and intranuclear areas in podocytes. HG reduced the
AMPKa (Thr172) phosphorylation of rat podocytes, and similarly, AGEs reduced the
AMPKa (Thr172) phosphorylation of mouse podocytes. The distributional and quanti-
tative changes in phospho-AMPKa caused by diabetic conditions were preventable
using AMPK activators, metformin, and 5-aminoimidazole-4-carboxamide-1b-riboside.
Conclusion: We suggest that diabetic conditions induce the relocation and suppression
of podocyte AMPKα, which would be a suggestive mechanism in diabetic podocyte
injury.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetic nephropathy is one of the major complications
of diabetes mellitus and currently the leading cause of end-n Society of Nephrology. Publi
c-nd/4.0/).
rics, College of Medicine, Chustage renal disease worldwide [1]. Early clinical manifestations
of diabetic nephropathy include hyperﬁltration and micro-
albuminuria, which could progress to overt proteinuria and
advanced renal injury. Accompanying morphological andshed by Elsevier. This is an open access article under the CC BY-NC-ND
ngbuk National University, 52 Naesudong-ro, Heungduk-gu,
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mesangial expansion, thickening of the glomerular basement
membrane, and effacement, denudation, and loss of podocytes
[1]. Accompanying biochemical alterations with pathological
changes lead to increases in the glomerular permeability as a
result of the impaired glomerular ﬁltration structure. These
changes would be caused by hyperglycemia, glycated proteins,
or irreversible advanced glycosylation end products (AGEs) via
various mechanisms, including biochemical pathways, signal-
ing, cytokines, and oxidative stress [2,3].
AMP (adenosine monophosphate)-activated protein kinase
(AMPK) is a ubiquitously expressed heterotrimeric kinase highly
conserved from yeast to plants and animals that plays a key role in
the regulation of energy homeostasis by coordinating multiple
metabolic pathways [4–6]. AMPK is composed of a catalytic α
subunit and regulatory β and γ subunits, each of which is encoded
by two or three distinct genes (α1, 2; β1, 2; γ1, 2, 3) [4–6]. The
kinase is activated by an elevated AMP/adenosine triphosphate
(ATP) ratio due to cellular and environmental stress, such as heat
shock, hypoxia, and ischemia [4–6].During energy stress as the
level of ATP begins to fall, there is a marked increase in the
cellular concentrations of AMP [4–7]. This increase in AMP leads
to the activation of AMPK via multiple mechanisms [7]. Once
activated, AMPK acts to restore energy homeostasis by phos-
phorylating multiple substrates that act both to stimulate
energy production and minimize energy consumption. The
relationship between AMPK activation and the beneﬁcial meta-
bolic effects provides the rationale for the development of new
therapeutic strategies for diabetic vascular diseases [8]. Thus,
pharmacological AMPK activation may, through signaling and
metabolic and genetic expression effects, reduce the risk of
diabetic and metabolic complications.
Over the past decade, the biology and biochemistry of the
AMPK pathway have been studied intensively in various
organs, such as the liver, skeletal muscle, and heart. Although
AMPK is abundantly expressed in the kidney [9,10], its role in
renal physiology and disease is less understood compared with
that in other organs [11,12]. In recent years, although interest
in AMPK in the kidney has intensiﬁed, only a few studies have
been conducted on the role of AMPKs in podocytes. We
hypothesized that diabetic conditions would induce changes
in AMPK in podocytes and that therapeutic modulation of
AMPK would be a potential target in the treatment of diabetic
podocytopathy.Methods
Preparation of rat diabetic renal tissue
All animal experimental procedures were performed according
to the guidelines for the care and use of animals established by
Yeungnam University, Gyeongsan, Korea. Diabetes was induced by
an intravenous injection of streptozotocin (STZ; Sigma Chemical
Co., St. Louis, MO, USA) at 45 mg/kg, freshly dissolved in 0.1M
sterile sodium citrate, pH 4.5, in 6-week-old rats weighing 180–
220 g. The rats were considered diabetic if their blood glucose
levels were above 200mg/dL at 48 hours after STZ injection.
Control rats were given an equivalent amount of saline via the tail
vein. The rats were sacriﬁced 48 hours, 4 weeks, and 10 weeks
after the induction of diabetes. Each group consisted of four
animals. Both kidneys were removed and used for the immuno-
ﬂuorescence assessment.Cell culture of rat glomerular epithelial cells and mouse
podocytes
Rat glomerular epithelial cells (GEpCs), cloned from pri-
mary rat glomerular cultures by Kreisberg [13], were charac-
terized by a sensitivity to puromycin amino nucleoside,
positive staining for Heymann antigen (gp330) and podoca-
lyxin, and negative staining for factor VIII [13–15]. GEpCs were
maintained as previously described [15]. Experiments were
performed with cells between passages 15 and 18. Condition-
ally immortalized mouse podocytes were kindly provided by
Dr Peter Mundel (University of Harvard, Boston, MA, USA)
and were cultured and differentiated for at least 2 weeks as
described previously [16].Preparation of culture additives and treatment conditions
Cells were serum-deprived to reduce the background 24
hours prior to each experiment and then exposed to glucose
and/or AGEs. Rat GEpCs or mouse podocytes were incubated
in culture medium containing either 5mM glucose (normal
glucose) or 30mM glucose (HG) without insulin. AGEs were
produced using the technique previously described by Ha et al
[15]. To imitate the long-term diabetic condition, AGEs were
added (5 mg/mL), and controls were established using unmo-
diﬁed bovine serum albumin (5 mg/mL). To exclude the effect
of additionally produced glycated proteins during culturing,
incubation did not last longer than 48 hours. The fetal bovine
serum was reduced to 0.5% at the last medium change to
reduce the background caused by any humoral effects of the
serum prior to protein and RNA extraction. For identiﬁcation
purposes, AGEs and bovine serum albumin were denoted
“A” and “B”, and glucose at 5mM and 30mM was denoted by
“5” and “30”, respectively. The meaning of each condition has
been described previously [15]. For AMPK activation, 5-ami-
noimidazole-4-carboxamide-1β-riboside (AICAR; Merck KGaA,
Darmstadt, Germany) and metformin (Daewoong Pharmaceu-
tical Co., Seoul, Korea) treatment was applied using concentra-
tions of 0.5mM and 2mM, respectively, for 24 hours. For AMPK
inhibition, compound C (Merck KGaA) was added to the
medium at a concentration of 5mM for 24 hours.Immunoblotting analysis for AMPK
The conﬂuently grown cell layers were incubated with
additives for various durations, extracted in protein extraction
solution (PRO-PREP; Intron, Seongnam, Korea) containing phe-
nylmethylsulfonyl ﬂuoride, ethylendiamine tetraacetic acid
(EDTA), pepstatin A, leupeptin, and aprotinin, and then the
protein concentrations were determined as previously described
[16]. For the immunoblotting assay, 25 mg of boiled extracts was
applied to 10% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) gels and transferred to polyvinylidene
ﬂuoride membranes (Bio-Rad Laboratories, Hercules, CA, USA).
Then, the membranes were air-dried and blocked in 3% fat-free
milk prior to incubation with monoclonal rabbit antiphospho-
AMPKα1⧸2 (Thr172) (Cell Signaling Technology, Danvers, MA,
USA) and polyclonal rabbit anti-AMPKα1⧸2(Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). As a loading control, anti-β-tubulin
antibody (Santa Cruz Biotechnology) was also used. After incuba-
tionwith horseradish peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnology), bands were detected using the ECL
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The density values were expressed as % of control (B5).Immunoﬂuorescence staining
Podocytes that were grown on type I collagen-coated glass
coverslips incubated for 24 hours were ﬁxed in 4% para-
formaldehyde, permeabilized in phosphate buffer solution,
blocked with 10% normal goat serum, and labeled with
monoclonal rabbit antiphospho-AMPKα1⧸2 (Thr172) (Cell Sig-
naling). F-actin was visualized with TRITC-phalloidin (Sigma
Chemical Co.). Primary antibody-bound specimens were incu-
bated with 1:500 (v/v) Alexa 488 for green and Alexa 594 for
red (Invitrogen, Eugene, OR, USA) conjugated secondary anti-
bodies at room temperature for 1 hour. Coverslips were
mounted in an aqueous mounting medium and viewed with
a ﬂuorescence microscope (BX51; Olympus, Tokyo, Japan).The
ﬂuorescence intensities were evaluated and calculated using
the public domain image-processing program IMAGEJ 1.46r
(National Institutes of Health, Bethesda, MD, USA).Statistical analysis
The results are expressed as mean 7 standard deviation.
The statistical signiﬁcance was assessed with a nonparametric
Kruskal–Wallis analysis of variance or Student t test. A P value
of less than 0.05 was considered statistically signiﬁcant.Figure 1. Distribution of phospho-AMPKα in normal and diabetic glom
capillary loop, and the densities of phospho-AMPKα in the diabetic rena
Magniﬁcation, 400. AMPK, adenosine monophosphate-activated protein kResults
Diabetic conditions relocate AMPKs in podocytes
In diabetic renal tissue, we found that phospho-AMPKα
stainings were located along the glomerular capillary loop, the
intensities of which were signiﬁcantly reduced according to
the diabetic duration (Fig. 1).
In cultured rat GEpCs, we found that phospho-AMPKα
stainings were diffusely located along with F-actin in the
peripheral cytoplasm in the control (B5) and osmotic control
(Aosm) (Fig. 2). However, diabetic conditions (B30, A5, and
A30) suppressed the intensities of phospho-AMPKα, especially
in peripheral cytoplasmic areas, which were somewhat dis-
sociated from the rearranged F-actin ﬁbers (Fig. 2).Diabetic conditions decrease the phosphorylation of AMPK
HG, including B30 and A30, but not A5, reduced the AMPKα
phosphorylation of rat GEpCs in a time-dependent manner by
36.2% and 25.9%, respectively, after correcting for the total
AMPK (n¼3) and similarly by 31.5% and 28.1%, respectively,
after correcting for the β-tubulin levels, compared with
the control (B5) (n¼3, Fig. 3A). The longer their exposure
durations were, the more prominent suppressions by AGEs
were found.
In mouse podocytes, neither AGEs (A5) nor HG (B30)
changed the AMPKα phosphorylation; however, both AGEseruli. In renal tissues, phospho-AMPKα staining is located along the
l tissues decreased according to diabetic durations (n¼4 per group).
inase.
Figure 2. Distributional changes of phospho-AMPKα in diabetic conditions. (A) Fluorescence spots of phospho-AMPKα are connected with F-actin
and are signiﬁcantly reduced and relocated to the internal cytoplasmic and perinuclear areas of mouse podocytes in diabetic conditions. Green arrows
in diagrams denote the initial peaks in the densities of phospho-AMPKα intensities. Magniﬁcation, 1000. AGE, advanced glycosylation end
products; AMPK, adenosine monophosphate-activated protein kinase; BSA, bovine serum albumin.
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24 hours by 45.8% (Po0.01) after correcting for the total
AMPK and similarly by 46.1% after correcting for the β-tubulin
levels compared with the control (B5) (n¼3, Fig. 3B). There
was also a somewhat reduced phospho-AMPKα response in
the osmotic control of AGEs (Aosm), which means that AGEs—
rather than HG—have a major suppressive effect on mouse
podocytes. At 48 hours, A30 reduced the AMPKα phosphoryla-
tion by 42.9% (Po0.05) after correcting for the total AMPK.
After correcting for the β-tubulin levels, AGEs (A5 and A30)—
rather than HG—also reduced the AMPKα phosphorylation by
40.6% (Po0.05) and 54.8% (Po0.01), respectively, compared
with the control (B5) (n¼3, Fig. 3B). Therefore, diabetic
conditions suppressed AMPKα phosphorylation, although the
similar effects were somewhat cell-speciﬁc.
AMPK activators ameliorate the changes in phospho-AMPKα
in podocytes
To further assess the involvement of AMPK modulating
agents in the regulation of AMPK, we incubated cells with
applied AMPK activators, AICAR and metformin, at concentra-
tions of 0.5mM and 2mM, respectively. Similar to the datashown in Fig. 2, diabetic conditions (B30, A5, and A30) and
compound C, an AMPK inhibitor, decreased and relocalized
the immunoﬂuorescent intensities of phospho-AMPKα to the
internal cytoplasm and to peri- and intranuclear areas of
mouse podocytes. Such changes were prevented by an AMPK
activator, metformin (Fig. 4A). In the Western blotting assay,
diabetic conditions (B30, A5, and A30) and compound C
suppressed phospho-AMPKα in mouse podocytes, similar to
that shown in Fig. 3B, a condition that was reversed by AICAR
and metformin (Fig. 4B). Therefore, diabetic conditions sup-
pressed and relocalized phospho-AMPKα in podocytes, and
AMPK activators modulated the podocyte injury induced by
diabetic conditions.Discussion
A number of physiological processes have been shown to
activate AMPK, including conditions that lead to an increase in
the intracellular AMP/ATP ratio (such as heat shock, hypoxia/
anoxia, ischemia, and glucose deprivation) and the calcium
concentration, along with the action of various hormones,
cytokines, and adipokines [4–6]. The activated form of AMPK is
Figure. 3. Diabetic conditions suppress phospho-AMPKα, as determined by Western blotting. The major band for phospho-AMPKα protein at
62 kDa decreased in high glucose conditions, B30 and A30, (A) at 24 hours and 48 hours in rat GEpCs and (B) in A30 at 48 hours in mouse podocytes.
Data on the densitometric analysis of the phospho-AMPKα/total AMPK or β-tubulin ratio are expressed as mean7SD (n¼3). Control (100%); the value
of the B5 condition. nPo0.05 and yPo0.01 versus control. AMPK, adenosine monophosphate-activated protein kinase; GEpCs, glomerular epithelial
cells; SD, standard deviation.
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of various downstream substrates. The net effect is a change in
local and whole-body energy utilization from an energy-
consuming state to an energy-producing state to restore the
energy balance. These ﬁndings, coupled with reports that AMPK
in the muscle is activated in response to exercise [17,18], have led
to an intense interest in developing AMPK activators as potential
therapies for type 2 diabetes and obesity [19].
AMPK and its activator, adiponectin receptor ADIPOR1,
localized at the plasma membranes of the glomerular cells,
including endothelium, mesangial cells, and podocytes, as well
as on parietal epithelial cells. Either adiponectin or AICAR led
to the activation of catalytic AMPK by phosphorylation in
isolated rat glomeruli [20]. This suggests that the activation
of glomerular AMPK by adiponectin or AICAR might play an
important role in the control of oxidative stress and cell
survival within the glomerulus.
It has been reported that AMPK activity is reduced in the
diabetic kidney [21–25]; however, the reduced AMPK activity
in the diabetic kidney does not appear to be related to altered
AMP or ATP levels [21]. Guo et al [21] have correlated the
reduced AMPK activity in STZ-induced diabetic rats to reduced
adiponectin levels, increased expression of connective tissue
growth factor, and increased triglyceride accumulation. The
changes in AMPK activity in the diabetic kidney do not appear
to be related to altered AMP or ATP levels. Cammisotto et al
[22] have demonstrated that the expression levels of ADIPOR1,
AMPKα(1), AMPKα(2), and AMPKβ(2) were increased in STZ-
treated diabetic rats, whereas phosphorylated active AMPK
levels were strongly decreased. They also demonstrated that
adiponectin through luminal ADIPOR1 activates AMPK, leading
to the inhibition of glycogen synthase.
Regarding podocytes, Lee et al [23] have shown that
reduced AMPKα subunit threonine (Thr) 172 phosphorylation
in the rat diabetic kidney and HG-treated cultured rat GEpCs,the same cells as ours, was associated with increased activa-
tion of hypertrophy marker proteins, including 4E binding
protein 1 and eukaryotic elongation factor 2, and mammalian
target of rapamycin (mTOR). Metformin and AICAR increased
renal AMPK phosphorylation, reversed mTOR activation, and
inhibited renal hypertrophy, without affecting hyperglycemia
in these models. We found the suppression of phospho-AMPKα
not only by HG but also by AGE in this experiment. In diabetic
models, Eid et al [24] have also found that high glucose diabetic
conditions in vitro and in vivo inactivated AMPK, upregulated
Nox4, enhanced NAD(P)H oxidase activity, and subsequently
induced podocyte apoptosis, which were inhibited by AMPK
activation. In the following experiment, they found that HG also
activated mTOR, which was downstream of AMPK [25]. Recently,
we found that angiotensin II, an important inducer of diabetic
injury, suppressed AMPKα phosphorylation in podocytes via
angiotensin II type 1 receptor and MAPK signaling, which may
cause podocyte dysfunction [26]. Piwkowska et al [27] have also
shown that metformin decreased the production of reactive
oxygen species, another major diabetic injury mediator, through
a reduction of NAD(P)H oxidase activity and increased AMPK
activity. Therefore, AMPK activator could prevent glucose-induced
oxidative stress in podocytes.
Reduced AMPK activity in the diabetic kidney has also been
linked to increased triglyceride accumulation because of the
reduced inhibitory phosphorylation of acetyl-CoA carboxylase
[21]. The increased triglyceride accumulation in the diabetic
kidney appears to increase the expression of connective tissue
growth factor, which is another mechanism that contributes
to diabetes-induced renal hypertrophy [21]. In addition, as
described above, reduced AMPK activity in the diabetic kidney
has been associated within creased renal tubular glycogen
accumulation [22]. In an obesity animal model, Sharma et al
[28] have also found that a low serum level of adiponectin is
associated with albuminuria and that adiponectin treatment
Figure 4. Effects of AMPK activators on the AMPKα-phosphorylation. (A) Diabetic conditions (B30, A5, and A30) and compound C decreased and
relocalized the immunoﬂuorescent intensities of phospho-AMPKα to the internal cytoplasm of mouse podocytes, which are recovered by metformin.
Magniﬁcation, 1000. (B) In the Western blotting assay, diabetic conditions (B30, A5, and A30) and compound C suppress the phospho-AMPKα of mouse
podocytes, which are reversed by AICAR and metformin. AGE, advanced glycosylation end products; AICAR, 5-aminoimidazole-4-carboxamide-1β-riboside;
AMPK, adenosine monophosphate-activated protein kinase; BSA, bovine serum albumin.
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reduced podocyte permeability to albumin and podocyte
dysfunction. Furthermore, adiponectin knockout mice exhibit
increased albuminuria and fusion of podocyte foot processes
[28]. They assumed that such effects appeared to be caused by
a reduction of oxidative stress, as adiponectin and AMPK
activation both reduced the protein levels of NAD(P)H oxidase
4 (Nox4) in podocytes [28].
Although the mechanism for the reduced AMPK activity in
the diabetic nephropathy is unclear, adiponectin may be asso-
ciated with AMPK activation, and reduced AMPK activity by
mTOR signaling, angiotensin II, and oxidative stress in diabetic
conditions would induce renal hypertrophy and apoptosis. A
similar suppression of AMPK activity was observed in podo-
cytes; this would be an important mechanism and a therapeutic
target for treating podocyte injuries induced by diabetic
conditions.
Another notable ﬁnding of our study is that diabetic
conditions induce the relocation of phospho-AMPKα from
the peripheral cytoplasm to the internal cytoplasm and peri-
and intranuclear areas in podocytes. Although we could not
ﬁnd any results on the relocation of podocytes AMPKα in
pathologic conditions, we suggest that its relocation might be
caused by the defect in trafﬁcking; therefore, it could induce
the decrease in its action at a signaling area in addition to the
reduced AMPK activity. Further observation on the cellularfractional changes of AMPKα is necessary to elucidate the
meaning of its relocalization.
In conclusion, we demonstrated that diabetic conditions
suppressed and relocalized phospho-AMPKα in podocytes, and
AMPK activators modulated the podocyte injury induced by
diabetic conditions. Therefore, the activation of AMPK signal-
ing might serve as a new therapeutic target for the treatment
of diabetic podocytopathy.Conﬂicts of interest
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